NCT01609179

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Infinity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A treatment protocol that enables patients to have continued access to IPI-926.

Detailed description

The extension protocol is a continuation of treatment with IPI-926, as administered to each individual patient during participation in their original IPI-926 protocol. Patients who are completing their participation in the original IPI-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with IPI-926 in the extension protocol.

Conditions

• Basal Cell Carcinoma
• Chondrosarcoma

Interventions

Type	Name	Description
DRUG	IPI-926	IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.

Timeline

• Start date: 2012-03-01
• Primary completion: 2012-10-01
• Completion: 2012-11-01
• First posted: 2012-05-31
• Last updated: 2012-11-14

Locations

2 sites across 1 country: United States